Publications by authors named "N M Blijlevens"
Objectives: The management of chronic myeloid leukemia (CML) now includes dose reduction (DR) and treatment-free remission (TFR). Evaluating the cost-effectiveness of lifelong-prescribed expensive tyrosine kinase inhibitors (TKIs) for CML is crucial. Prior cost-effectiveness evaluations state that imatinib is the favorable frontline TKI.
View Article and Find Full Text PDFBackground: Dose reduction of tyrosine kinase inhibitors (TKIs) is an option for some chronic myeloid leukemia (CML) patients to minimize side effects while maintaining efficacy. Shared decision-making (SDM) and patient decision aids (PDAs) are advocated to make informed choices such as reducing the dose of TKIs. This paper describes the development and alpha-testing of a PDA for patients with CML receiving TKI dose reduction.
View Article and Find Full Text PDFBackground: α2-Antiplasmin (A2AP) deficiency is a rare and often unidentified disorder characterized by increased fibrinolysis and subsequent bleeding. Global hemostasis assays may increase insight into the altered coagulation and fibrinolysis in these patients.
Objectives: To explore thrombin and plasmin generation profiles in A2AP-deficient patients, corresponding A2AP activity levels and associated bleeding phenotypes.
Article Synopsis
- Oral focus screening before hematopoietic cell transplantation (HCT) is critical, yet the impact of chronic dental issues on post-transplant health is not well understood.
- A study of 500 patients highlighted that nearly half had untreated chronic dental problems, and those with three or more issues stayed in the hospital five days longer on average.
- The research found that while having multiple dental foci increased hospital length of stay, it did not significantly affect early mortality rates post-HCT.